Trial
NCT03973918
Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
National Cancer Institute (NCI); Pfizer
Condition
High Grade Glioma
Intervention
Encorafenib
Why stopped
NCI decided to terminate ABTC Consortium due to NCI moving in different direction for Brain Cancer
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-31